Plasma antibodies against heat shock protein 70 correlate with the incidence and severity of asthma in a Chinese population

Miao Yang1, Tangchun Wu*1, Longxian Cheng2, Feng Wang1, Qingyi Wei1 and Robert M Tanguay*3

Address: 1Institute of Occupational Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China, 2Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China and 3Laboratory of Cell and Developmental Genetics, Dept Medicine, Faculty of Medicine, Pav. C.E. Marchand, Université Laval, Quebec, G1K 7P4, Canada

Email: Miao Yang - y2000yangmiao@hotmail.com; Tangchun Wu* - wut@mails.tjmu.edu.cn; Longxian Cheng - chenglongxian@sina.com; Feng Wang - Carl wwang@hotmail.com; Qingyi Wei - weiqingyi@yahoo.com; Robert M Tanguay* - robert.tanguay@rsvs.ulaval.ca

* Corresponding authors

Abstract

Background: The heat shock proteins (Hsps) are induced by stresses such as allergic factors and inflammatory responses in bronchi epithelial cells and therefore may be detectable in patients with asthma. However, the etiologic link between anti-Hsps and asthma (its severity and related inflammatory responses such as interleukin-4 and immunoglobulin E) has not been established. We determined whether antibodies against Hsp60 and Hsp70 were present in patients with asthma and evaluated their associations with risk and severity of asthma.

Methods: We determined the levels of anti-Hsp60 and anti-Hsp70 by immunoblot and their associations with risk and symptom severity of asthma in 95 patients with asthma and 99 matched non-symptomatic controls using multivariate logistic regression analysis.

Results: Compared to the controls, asthma patients were more likely to have detectable anti-Hsp60 (17.2% vs 5.1%) and anti-Hsp70 (33.7% vs 8.1%) (p ≤ 0.001). In particular, the presence of anti-Hsp70 was associated with a greater than 2 fold risk for asthma (adjusted OR = 2.21; 95% CI = 1.35–3.59). Furthermore, both anti-Hsp60 and anti-Hsp70 levels were positively correlated with symptom severity (p < 0.05) as well as interleukin-4 and immunoglobulin E (p < 0.05). Individuals with antibodies against anti-Hsp60 and anti-Hsp70 were more likely to have a family history of asthma (p < 0.001) and higher plasma concentrations of total immunoglobulin E (p = 0.001) and interleukin-4 (p < 0.05) than those without antibodies.

Conclusions: These data suggest that anti-Hsp60 and especially anti-Hsp70 correlate with the attacks and severity of asthma. The underlying molecular mechanisms linking antibodies to heat shock proteins and asthma remain to be investigated.

Background

Heat shock proteins (Hsps) are highly conserved proteins inducible in response to a wide variety of stresses (such as exposure to heat) and pathological (viral, bacterial or parasitic infections, and inflammation) or physiological (growth factors, cell differentiation, and hormonal
stimulation) stimuli [1,2]. There are six main Hsp families (i.e., Hsp110, Hsp90, Hsp/Hsc70, Hsp60, Hsp40, and Hsp10-30) categorized on the basis of their apparent molecular masses detected by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Hsps are involved in various biological functions including 1) intracellular chaperones of naive, aberrantly folded or mutated proteins, 2) cytokines of signal transduction cascades involved in inflammatory response, and 3) cytoprotective agents in response to the aforementioned stress stimuli [1,3,4]. In addition, Hsps are also involved in transport of proteins and peptides through cellular compartments, and can bind to endogenous antigenic peptides and transport them to the major histocompatibility complexes [5,6]. This suggests that Hsps may modulate immune and inflammatory responses and may be involved in the pathogenesis and/or be markers for risk and prognosis of certain diseases including asthma [7-13], given that many of the stress stimuli mentioned above are factors that can induce attacks of asthma.

Asthma is a multifactorial and likely multigenic immune inflammatory disease of the upper airways, arising from complex interactions among environmental and genetic factors [14,15]. These factors may induce Hsp60 and Hsp70 in bronchi epithelial cells during the development of asthma [16]. Some Hsps present as self-antigens to the immune system, resulting in the production of autoantibodies in patients with inflammatory diseases and immune disorders after infections by bacteria, mycobacteria and Chlamydia [17-19]. Studies have demonstrated that these autoantibodies against Hsps were involved in the pathogenesis and/or prognosis of some diseases [8,20-23].

Up to now, few studies investigated possible associations of autoantibodies to human Hsps with the severity of asthma. In the present study, we determined the presence of autoantibodies to human Hsp60 and Hsp70 in 193 subjects with (n = 95) and without (n = 99) asthma by immunoblot analysis, and evaluated the associations of these autoantibodies with asthma severity and their correlation with interleukin-4 (IL-4) and immunoglobulin E (IgE) both involved in the development of asthma, by using multivariate logistic regression analyses.

### Methods

#### Subjects and groups

This 95 patients with asthma (54 males and 41 females) and 99 healthy, age-matched non-asthmatic controls (64 males and 35 females) were residents living in the same geographic area. Patients and controls were from Wuchang, one of the three cities of Wuhan and were all of Han nationality. Their age ranged from 10 to 45 years old (Table 1). All 95 patients were diagnosed according to diagnostic criteria and principles of management of asthma proposed by the American Thoracic Society [24] and did not have other pulmonary, cardiovascular and gastro-duodenal diseases. A standardized questionnaire was completed for each individual by physicians with extensive experience in allergic and immune diseases to obtain demographic information and known risk factors for asthma including personal and family history of asthma and frequency of attacks. Selection criteria for the controls included the absence of any personal history of asthma. Health examination and physical sign findings such as wheezing and forced expiratory volume (FEV%Pre) were also recorded. Neither patients nor controls had any history of chronic diseases such as cancer, diabetes, cardiovascular diseases and gastro-duodenal diseases. Patients with asthma were grouped by symptom severity and medication use according to the 2002 Global Initiative for Asthma Guidance [25] as intermittent, mild persistent, moderate persistent and severe persistent. Venous blood was collected into heparinized tubes to separate plasma for the detection of anti-Hsp60 and anti-Hsp70 as well as IgE and IL-4. Plasma samples from patients and controls were stored in aliquots at -80°C and thawed only once immediately before the tests were performed. Written informed consent was obtained from patients and controls, and the study was approved by the Tongji Medical College Ethics Committee.

### Table 1: Comparison of selected variables between patients with asthma and healthy controls

|                        | Patients with asthma (n = 95) | Control subjects (n = 99) | P value |
|------------------------|------------------------------|--------------------------|---------|
| Sex (M/F)              | 54/41                        | 64/35                    | 0.266   |
| Age (years, mean ± SD) | 28.2 ± 15.8                  | 29.1 ± 13.9              | 0.680   |
| Attack once a week or a day (yes/no) | 95/95 | 0/99 | <0.000 |
| Sign (wheezing) (yes/no) | 95/95 | 0/99 | <0.000 |
| FEV%Pre                | 58.4 ± 18.9                  | 96.5 ± 9.8               | <0.001  |
| IgE (IU/ml, mean ± SD) | 486.9 ± 595.5                | 75.8 ± 124.9             | <0.001  |
| IL-4 (ng/L, mean ± SD) | 31.7 ± 17.1                  | 5.1 ± 3.8                | <0.001  |
Determination of anti-Hsp60 and anti-Hsp70

Recombinant human Hsp60 and inducible Hsp70 were obtained through the expression of corresponding cDNA in NaCl-induced E. coli GJ1168 cells using pET30 (Novagen) as the expression vector [26]. Approximately 10–15 µg of recombinant human Hsp60 or Hsp70 was loaded on each SDS-PAGE gel without combs, separated, and transferred by electrophoresis to nitrocellulose membranes. The band containing Hsp60 or Hsp70 was cut into 2 mm × 3 mm pieces and marked with a small red dot on the protein side of the membrane. These membrane pieces were placed in individual wells of an ELISA plate, rinsed with PBS, saturated with 100 µl of blocking buffer (PBS containing 5% skim milk powder) for 1 h at 37°C with gentle agitation and washed with PBS-0.05% Tween 80 for 5 min. The plasma diluted 1:10, 1:20, 1:40 and 1:80 in 100 µl PBS containing 5% skim milk powder was incubated with the membrane pieces at 37°C for 2 h with gentle agitation. After washing the membrane pieces six times (10 min each) with 200 µl PBS-0.05% Tween 80, 100 µl of HRP labelled goat anti-human IgG (Sigma) in blocking buffer (1:2500) was added and the incubation continued at 37°C for 1 h. The membrane pieces were washed again six times (10 min) with 200 µl PBS-0.05% Tween 80. The presence of anti-Hsp60 or anti-Hsp70 was then revealed with DAB (3,3-diaminobenzidine tetra hydrochloride) for 3–5 min. A visible brown band on the membrane piece was regarded as a positive test and a colourless membrane as a negative test [21,22]. An example of the microblot technique is shown in Figure 1. Samples were scored in a double blind manner by three different investigators.

Detection of plasma IgE and IL-4

Total IgE was measured in plasma by using a fluorescence enzyme immunoassay kit from Bayer Company (Leverkusen, Germany). IL-4 was determined using a commercial enzyme-linked immunosorbent assay kit from OptEIA (Phar mingen, California, U.S.A). Each sample was tested in duplicate by a series of dilutions using a standard provided with the kit.

Statistical analyses

All the continuous data (e.g., age, FEV1, IgE, IL4) were presented as the mean ± standard deviation (SD) and analysed by the Student's t test. Frequency data (e.g., sex) were analysed by the Chi-square test. The associations were estimated by fitting univariate and multivariate logistic regression models. Statistical inferences were based on a significance level of 0.05. All analyses were two-sided and performed by using the Statistical Package for Social Sciences (SPSS) software (Version, Chicago).

Results

The patient and control groups comprised 56.8% and 64.6% of males, respectively, and had mean ages of 28.2 and 29.1 years, respectively (Table 1). All patients had regular asthma attacks and sign of wheezing, while none of the controls showed any of these signs. Asthma patients had a significantly lower FEV1%Pre than the controls (58.4 vs 96.5, p < 0.001). In addition, the asthma patients had significantly higher concentrations of total IgE and IL-4 than the controls (p < 0.001 for all comparisons).

Presence of anti-Hsp60 and anti-Hsp70 in plasma

We first looked for the presence of anti-Hsp60 and anti-Hsp70 in plasma at dilutions of 1:10 to 1:80 in the patients with asthma and in the matched controls. At a dilution of 1:10, asthma patients had a significantly higher positive rate of anti-Hsp60 than the controls (17.9% vs 5.1%, p = 0.001). In the case of Hsp70, antibodies were observed in 33.7% of patients as compared to 8.1% in the controls at a dilution of 1:10 (p < 0.001). At plasma dilutions between 1:20 to 1:80, the difference in the detection rates of both anti-Hsp60 and anti-Hsp70 between the patients and controls remained highly significant (Table 2). The combined detection rate of both anti-Hsp60 and anti-Hsp70 in plasma at dilution 1:10 was also globally much higher in the asthma patients (38.9%) than in the controls (9.1%).

Association between anti-Hsp60 and anti-Hsp70 with risk for asthma

Further analysis for asthma risk factors (sex, age, family history) and anti-Hsp60 and anti-Hsp70 was carried out
by using a multivariate logistic regression model built with a forward stepwise selection procedure (p values for entry and removal, 0.10) and also based on clinical experience. The results in Table 3 show a statistically significant positive association between the presence of anti-Hsp70 and risk for asthma (p = 0.001), representing a greater than 2-fold increased risk for asthma (adjusted OR = 2.21; 95% CI = 1.35~3.59) (Table 3). However, no significant association of anti-Hsp60 with risk for asthma was found (p = 0.161).

**Table 3: Multivariate logistic regression analysis of the association between anti-Hsp60 and anti-Hsp70 with risk for asthma**

| Variables* | Adjusted Regression coefficient | Standard error | χ² Value | P value | OR (95% CI)** |
|------------|---------------------------------|----------------|----------|---------|---------------|
| Constant   | -0.977                          | 0.509          | 3.676    | 0.055   | 1.48 (0.79~2.76) |
| Sex        | 0.392                           | 0.318          | 1.519    | 0.218   | 1.48 (0.79~2.76) |
| Age        | 0.017                           | 0.109          | 0.026    | 0.872   | 1.02 (0.82~1.26) |
| Family history | 0.602                          | 0.219          | 8.215    | 0.005   | 2.01 (1.25~3.25) |
| Anti-Hsp60 | 0.459                           | 0.328          | 1.965    | 0.161   | 1.58 (0.83~3.01) |
| Anti-Hsp70 | 0.794                           | 0.248          | 10.224   | 0.001   | 2.21 (1.35~3.59) |

*The dependent variable is the status of asthma patient or control; the independent variables included Sex: 0 = male and 1 = female; Age: continuous variable in years; Family history: 0 = no and 1 = yes; Anti-Hsp60: 0 = negative and 1 = positive; Anti-Hsp70: 0 = negative and 1 = positive.

**OR, odds ratio, and CI, confidence interval.

Correlation of anti-Hsp60 and anti-Hsp70 with the severity of asthma

To understand the possible significance of the anti-Hsp60 and anti-Hsp70 in asthma, we analyzed the correlation of anti-Hsp60 and anti-Hsp70 with the severity of asthma. Table 4 shows that there was a significant increase of positive rates and dilutions of anti-Hsp60 and anti-Hsp70 as the severity of asthma increased. This table also shows that there were significantly positive correlations of anti-Hsp60 and anti-Hsp70 with the numerical categories of symptom severity (p < 0.05).

**Differences in the levels of IgE and IL-4 between asthma patients with positive and negative anti-Hsps**

We finally compared the levels of IgE and IL-4, two important known risk factors for asthma, in the 95 asthma patients who were either positive (37 patients) or negative (58 patients) for the presence of anti-Hsp60 and anti-Hsp70. The patients positive for anti-Hsps were more likely than the antibody-negative group of patients to report a family history of asthma (48.6% Vs 13.8%, p < 0.001) and had higher concentrations of total IgE (758.2 Vs 313.9, p = 0.001) and IL-4 (36.9 Vs 28.5, p = 0.019) (Table 5). Further analysis showed that the presence of either anti-Hsp60 or anti-Hsp70 or both was significantly correlated with the levels of IgE and IL-4 in asthma patients (Table 6) (p < 0.05). These preliminary data also
indicated a positive correlation between the presence of these autoantibodies and the severity of the disease \((r = 0.461, p < 0.001\) for anti-Hsp60 and \(r = 0.538, p < 0.001\) for anti-Hsp70) (Table 6) as well as a statistically significant correlation between anti-Hsp70 and anti-Hsp60 \((r = 0.485, p < 0.001)\) by using the rank correlation analysis.

**Discussion**

The patients included in the present study had frequent asthmatic attacks, with signs of wheezing and higher levels of IgE and IL-4 and low levels of FEV1 \%Pre that are characteristics of asthma. We found that these asthma patients also had a significantly higher incidence of autoantibodies against combined Hsp60 and Hsp70 than the matched non-asthmatic controls and that, in particular, the presence of anti-Hsp70 was associated with asthma. Furthermore, there was a significant positive correlation between anti-Hsp60 and anti-Hsp70 and symptom severity of asthma. Thus among asthma patients, those who had positive anti-Hsp60 and anti-Hsp70 were more likely to report a family history of asthma and had higher levels of IgE and IL-4 than those without such antibodies. These findings provide evidence to support the hypothesis that the presence of anti-Hsp60 and especially anti-Hsp70 in asthma patients is strongly associated with asthma and the presence of these antibodies may predict symptom severity of asthma and provide new strategies for diagnosis and perhaps treatment of this disease.
Asthma is an immune and inflammatory disease, arising from complex interactions among genetic and environmental factors including bacterial or viral infection [14,15]. The production of autoantibodies against Hsps may result from genetic factors, infection, denaturation and release of Hsps as a result of cell damage, and the presence of antigen-specific lymphocytes [22,23].

Hsps are often the target of humoral and T cell-mediated immune responses to infection and may provide a link between the immune response to infection and autoimmunity caused by T lymphocyte cross-reactivity among Hsps of different origins [8,27,28]. It remains to be determined whether there is a relationship between the induction of Hsp70 and production of plasma autoantibodies against this Hsp and whether there is a cross-response of induced Hsps and autoantibodies against Hsps before and during the development of asthma. However, there are several lines of evidence that support an association between anti-Hsp60 and anti-Hsp70 and symptom severity in asthma patients. Firstly, as molecular chaperones, Hsps facilitate the synthesis, folding, assembly and intracellular trafficking of many functional proteins [3,29] and protect cells and organs against different types of damages [30,31] as observed in transient protection from ischemic injury in whole organs such as heart, brain and kidney [31-34]. Hsp70 has also been suggested to play an autoprotective role in asthma and lung injury [35-37]. Secondly, autoantibodies against Hsps may have significant roles in the pathogenesis and prognosis of diseases. For example, Shinghai et al reported the presence of antibodies against Hsps in patients with autoimmune liver diseases and suggested that the presence of anti-Hsp70 was an indicator for the disease activity of primary biliary cirrhosis [8]. Earlier results from our lab also suggested that the presence of such antibodies might help assess if workers are experiencing abnormal stress within their living and working environment [21-23]. Xu et al and Schett et al have shown that mycobacterial Hsp65 may serve as an antigen to instigate chronic immune responses characteristic of human atherosclerosis. These antibodies were sustained among patients with the most severe degree of underlying atherosclerosis and were demonstrated to predict 5-year mortality [11,12,20]. Thirdly, enhanced expression of Hsp70 has been detected in bronchi and alveolar macrophages of patients with asthma and correlated with intrapulmonary eosinophilia, airway inflammation, hyperresponsiveness of bronchi [38], and severity of the disease [14,35,39]. A cross-response of induced plasma and cellular Hsps and autoantibodies against Hsps in human, has been suggested to play a role in the development and prognosis of atherosclerosis [40,41]. However, it is still unknown whether there is a cross-response between the induction of Hsps in bronchi of patients with asthma and the presence of anti-Hsps and its biological effects.

The development of most immune diseases depends on the cytokines interleukin-2 and interferon-γ produced by type 1 helper T cells (Th1), whereas the development of allergic diseases requires IL-4 and IL-5, both of which are produced by type 2 helper T cells (Th2). The reciprocal down-regulation of Th1 cells by Th2 cytokines raises the possibility that these cytokines are involved in allergy or immunity [42]. IL-4 is one of the first signals for a switch to the synthesis of IgE and IL-4 binds to receptors on B cells to induce and amplify the synthesis of IgE [43]. There is a cross-linking of IgE with allergens to activate a series of response seen in asthma [44]. Epidemiological and clinical observations have linked IgE antibodies to the severity of asthma and the initial and sustained responses of the airways to allergens [45,46]. At this time, the molecular events that link antibody to Hsp70 to the production of IL-4 and IgE and the interaction among these factors in patients with asthma remain to be investigated.

**Conclusions**

The present study showed that there was a significant increase in positive rates of antibodies against Hsp60 and Hsp70 in patients with asthma and that the presence of autoantibodies against Hsp70 was associated with the severity of asthma. The presence of anti-Hsp70 associated with a high risk of asthma was also correlated with the family history of asthma and higher levels of total IgE and IL-4 in the patients. These results suggest that anti-Hsp70 correlate with the pathogenesis of asthma, but the precise underlying molecular mechanisms for these interactions remain to be established.

**Authors’ contributions**

MY and LC performed the immunoblot assays, the acquisition of data and wrote the first draft of the manuscript. FW carried out the collection and statistical analysis of data. QW was responsible for the analysis and interpretation of data, and critical revision of the manuscript. TW and RMT initiated the project, designed the experiments, and wrote the manuscript.

**Acknowledgements**

We are particularly grateful to all individuals who voluntarily participated in the study and to the many members of the medical personnel of HuBei College of Traditional Medicine for their generous help in the examination and sampling of subjects. This study was supported by grants from the National Key Basic Research and Development Program (2002CB512905), the National Natural Science Foundation of China (NNSFC 30200227), an exchange Program between the Canadian Institutes of Health Research (CIHR) and the NNSFC (to TW, RMT) and an operating grant from the CIHR (to RMT).
References

1. Morimoto RI, Tissieres A, Georgopoulos C. Progress and perspectives in the biology of heat shock proteins and molecular chaperones. In The Biology of Heat Shock Proteins and Molecular Chaperones. Edited by: Morimoto RI, Tissieres A, Georgopoulos C. New York: Cold Spring Harbor Laboratory Press; 1994:1-30.

2. Micheaud S, Marin R, Tanguy RM: Regulation of heat shock gene induction and expression during Drosophila development. Cell Mol Life Sci 1997, 53:104-113.

3. Hightower LE: Heat shock, stress protein, chaperones, and proteotoxicity. Cell 1991, 66:191-197.

4. Asea A, Kraeft SK, Kurt-Jones E, Stevenson MA, Chen LB, Finberg R, Koo GC, Calderwood SK: HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its activity as a chaperone and cytokine. Nat Med 2000, 6:435-440.

5. Singh-Jasuja H, Arnold-Schild D, Schild H: Stress Chaperones. London: Kluwer Academic Publishers; 1995.

6. Hightower LE: Analysis of hsp70 gene polymorphism in allergic individuals. J Allergy Clin Immunol 1999, 104:555-557.

7. Hahn DL, Peeling RW, Dillon E, McDonald R, Saikku P: Autoantibodies against heat shock protein 65 mediates persistent Chlamydia trachomatis infection in vitro. Proc Natl Acad Sci USA 1993, 90:3998-4002.

8. Meidinger E, Tabar A, Kragballe K, Winkelmann RK, Aasen T, Bortfeld T, Fenger R, Hansen SB, Hentzer M, Hviid I: Reduced expression of heat shock protein 70 in melanoma cells by interferon-γ. Cell Stress Chaperones 2003, 8:86-92.

9. Xu C, Chen S, Liu J, Hai T, Lu Q, Sun E, Wang R, Tanguy RM, Wu T: Association of HSP70 and genotoxic damage in lymphocytes of workers exposed to coke-oven emission. Cell Stress Chaperones 2002, 7:396-402.

10. Xu Q, Williet J, Marosi M, Kleindienst R, Oberhollenzer F, Kiechl AS, Stulnig T, Lefl G, Wick G: Association of serum antibodies to heat shock protein 65 with carotid atherosclerosis. Lancet 1993, 341:255-259.

11. Xu Q, Kiechl S, Mayr M, Metzler B, Egger G, Oberhollenzer F, Wick G: Association of serum antibodies to heat shock protein 65 with carotid atherosclerosis: clinical significance determined in a follow-up study. Circulation 1999, 100:1169-1174.

12. Blachere NE, Srivastava PK: Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors. Semin Cancer Biol 1995, 6:349-355.

13. Braun-Fahrländer C, Riedler J, Herz U, Edler W, Waser M, Grize L, Maisch S, Carr D, Gerlach F, Bue A, Launer R, Schierl R, Renz H, Nowak D, von Mutius E: Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 2002, 347:869-877.

14. Aron Y, Busson M, Polls BS, Dusser D, Lockhart A, Swierczewski E, Favier F: Analysis of hsp70 gene polymorphism in allergic asthma. Allergy 1999, 54:165-170.

15. Vignola AM, Chanez P, Polla BS, Vic P, Godard P, Bouquet J: Increased expression of heat shock protein 70 on airway cells in asthma and chronic bronchitis. Am J Resp Cell Mol Biol 1995, 13:63-70.

16. Hahn DL, Peeling RW, Dillon E, McDonald R, Saikku P: Serologic markers for Chlamydia pneumoniae in asthma. Ann Allergy Asthma Immunol 2000, 84:227-233.

17. Lemsanske RF Jr: Limited clinical trials of predatory asthma. Pediatr Clin North Am 2000, 50:555-575.

18. Lemanske RF Jr: Is asthma an infectious disease? Thomas A. Neff lecture. Chest 2003:385S-390S.

19. Schett G, Xu Q, Amberger A, Van Der Zee R, Rechies H, Willette J, Wick G: Autoantibodies against heat shock protein 65 mediate endothelial cytotoxicity. J Clin Invest 1995, 96:2569-2577.

20. Wu T, Yuan Y, Wu Y, He H, Zhang G, Tanguy RM: Presence of antibodies to heat stress proteins in workers exposed to benzene and in patients with benzene poisoning. Cell Stress Chaperones 1998, 3:161-167.

21. Wu T, Chen S, Sun Y, Xiao C, Wang C, Pan Q, Wang Z, Xie M, Mao Z, Wu Y, Tanguy RM: Presence of antibody against the inducible Hsp71 in patients with acute heat-induced illness. Cell Stress Chaperones 2001, 6:113-120.

22. Wu T, Ma J, Chen S, Sun Y, Xiao C, Gao Y, Wang R, Poudrier J, Dargis M, Currie RW, Tanguy RM: Association of plasma antibodies against the inducible Hsp70 with hypertension and harsh working conditions. Cell Stress Chaperones 2001, 6:394-401.

23. American Thoracic Society: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987, 136:225-244.

24. US Department of Health and Human Services: Global initiative for asthma: Global strategy for asthma management and prevention. Bethesda, Maryland: National Institute of Health, National Heart, Lung, and Blood Institute; 2002.

25. Tanguy RM, Wu Y, Khandjian EW: Tissue-specific expression of heat shock stress proteins of the mouse in the absence of stress. Dev Genet 1993, 14:112-118.

26. Beatty WL, Byrne GI, Morison RP: Morphologic and antigenic characterization of immunocompetent cells immmunized persistently with the inducible Hsp70 protein in mice. J Immunol 1994, 152:1751-1757.

27. Hartl F-U: Molecular chaperones in protein folding. Nature 1996, 381:571-580.

28. Anglicides CE, Lazaridis I, Pagoulatos GN: Constitutive expression of heat shock protein 70 in mammalian cells confers thermotolerance. Eur J Biochem 1991, 199:35-39.

29. Li GC, Li LY, Liu K, Mak JK, Chen L, Lee WFM: Thermal response of rat fibroblasts stably transfected with the human 70 kDa heat shock protein encoding gene. Proc Natl Acad Sci USA 1991, 88:1681-1685.

30. Plummer JC, Krueger AM, Currie RW, Kontoyiannis D, Kollas G, Pagoulatos GN: Transgenic mice expressing the human inducible Hsp70 have hippocampal neurons resistant to ischemic injury. Cell Stress Chaperones 1997, 2:162-167.

31. Plummer JC, Ross BM, Currie RW, Anglicides CE, Kazlaris H, Kollas G, Pagoulatos GN: Transgenic mice expressing the human heat shock protein 70 have improved post-ischemic myocardial recovery. J Clin Invest 1995, 95:1845-1860.

32. Beck FX, Neuhofer W, Muller E: Molecular chaperones in the kidney: Distribution, putative roles, and regulation. Am J Physiol Renal Physiol 2000, 279:F203-F215.

33. Bertorelli G, Bocchino V, Zhou X, Zanini A, Bernini MV, Davila R, Di Comite V, Grima P, Olivieri D: Heat-shock protein 70 upregulation is related to HLD-DR expression in bronchial asthma. Effects of inhaled glucocorticoids. Clin Exp Allergy 1998, 28:551-560.

34. Hong HR, Wispe JR: The stress response and the lung. Am J Physiol 1997, 273:L1-L9.

35. Bonay M, Soler P, Riquet M, Battesti JP, Hance AJ, Tazi A: Expression of heat shock proteins in human lung and lung cancers. Am J Respir Cell Mol Biol 1994, 10:453-461.

36. Tong W, Luo W: Heat shock proteins' mRNA expression in asthma. Respiratory Care 2000, 5:227-230.

37. Rha YH, Taube C, Haczku A, Joetham A, Takedi K, Duez C, Siegel M, Aydintug MK, Bohn WK, Dakhama AH: 'Indwelling' Effect of microbially induced heat shock proteins on airway inflammation and hyperresponsiveness. J Immunol 2002, 169:5300-5307.

38. Perschinka H, Mayr M, Millong G, Mayerl C, Van Der Zee R, Morri- son SG, Morrison RP, Xu Q, Wick G: Cross-reactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis. Arterioscl Thromb Vasc Biol 2003, 23:1060-1065.

39. Mandal K, Jahaniri M, Xu Q: Autoimmunity to heat shock proteins in atherosclerosis. Autoimmun Rev 2004, 3:31-37.

40. Hopfensperger JT, Parr SK, Hopp RJ, Towsley RG, Agrawal DK: Mycobacterial antigens attenuate late phase response, airway hyperresponsiveness, and bronchoalveolar lavage eosinophilia in a mouse model of bronchial asthma. Int Immunopharmacol 2001, 1:1743-1751.

41. Busse WW, Lemanske RF Jr: Asthma. N Engl J Med 2001, 344:350-362.

42. Barbaric AL, Jorina G: Molecular mechanisms of immunoglobulin E regulation. Int Arch Allergy Immunol 1998, 115:257-269.
45. Burrows B, Martinez FD, Halone M, Barbee RA, Cline MG: Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989, 320:271-277.

46. Varner AE, Lemanske RF Jr: The early and late response to allergen. In Asthma and rhinitis Edited by: Busse WW, Holgate ST. London: Blackwell Science; 2000:1172-1185.